Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9GZZ9
UPID:
UBA5_HUMAN
Alternative names:
ThiFP1; UFM1-activating enzyme; Ubiquitin-activating enzyme E1 domain-containing protein 1
Alternative UPACC:
Q9GZZ9; A6NJL3; D3DNC8; Q96ST1
Background:
Ubiquitin-like modifier-activating enzyme 5 (Ubiquitin-activating enzyme E1 domain-containing protein 1, ThiFP1, UFM1-activating enzyme) plays a pivotal role in the ufmylation process. This enzyme catalyzes the initial step by activating UFM1, a ubiquitin-like modifier, through an ATP-dependent mechanism. It facilitates the transfer of UFM1 to target proteins via the E2-like enzyme UFC1, crucial for cellular processes such as reticulophagy, especially under endoplasmic reticulum stress conditions.
Therapeutic significance:
Ubiquitin-like modifier-activating enzyme 5 is implicated in severe diseases such as Developmental and epileptic encephalopathy 44 and Spinocerebellar ataxia, autosomal recessive, 24. These conditions highlight the enzyme's critical role in neurological development and function, suggesting that targeting this protein could offer novel therapeutic avenues for these debilitating disorders.